Full-Time

Clinical Specialist

Cryo Nerve Block

AtriCure

AtriCure

1,001-5,000 employees

Sells ablation devices for atrial fibrillation

No salary listed

Birmingham, UK + 2 more

More locations: Oxford, UK | Bath, UK

In Person

Field-based role requiring travel throughout the assigned territory, up to 70%.

Bachelor's

Category
Solution Engineering
Required Skills
Microsoft Office
CRM
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to AtriCure

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific, technical, healthcare, or related field.
  • Strong attention to detail and organizational skills.
  • Experience working in an operating room environment; cardiothoracic, orthopedic, or related surgical experience gained through industry or clinical practice is preferred but not required.
  • Excellent presentation, communication, and customer relationship management skills.
  • Strong interpersonal skills with a proven ability to build and maintain professional relationships.
  • Ability to communicate and collaborate effectively with stakeholders at all levels.
  • Strong problem-solving and troubleshooting abilities.
  • Proficiency in Microsoft Office applications, including PowerPoint, Outlook, Excel, and Word.
  • A valid driver's license and ability to travel throughout the assigned territory.
  • Willingness to support early morning, daytime, and evening surgical cases as required.
  • Ability to travel up to 70%.
Responsibilities
  • Provide in-theatre support during surgical procedures utilizing Cryo nerve block technology.
  • Drive utilization and adoption of Cryo nerve block therapy within existing accounts by building clinical advocacy, increasing procedural usage, and supporting long-term customer success.
  • Assist healthcare professionals with technical and procedural questions during cases.
  • Maintain a strong understanding of surgical workflows and operating room protocols.
  • Train surgical and operating room staff personnel in the use of company devices.
  • Educate surgeons, anesthetists, nurses, and operating room personnel on the safe and effective use of Cryo nerve block technology.
  • Deliver in-service training and product demonstrations.
  • Serve as a trusted clinical resource to customers by answering questions and demonstrating best practice.
  • Partner with Regional Sales Managers and clinical specialists to identify growth opportunities within existing accounts.
  • Assist with physician education events and conferences.
  • Provide guidance and support for physicians during live surgical procedures, including utilization and operation of company technology.
  • Conduct training for surgeons and medical staff using didactic and hands-on approaches.
  • Provide technical and clinical support during surgical procedures.
  • Call on surgeons and support staff as necessary to discuss AtriCure technology, training programs, and clinical programs and trials.
  • Work in a team environment with Sales, Marketing, and Engineering.
  • Communicate frequently and report on case notes and product and clinical feedback.

AtriCure designs and sells medical devices to treat atrial fibrillation and related heart conditions. Its products include ablation systems, left atrial appendage management devices, and cryoablation tools used in open-heart and minimally invasive surgeries; these devices deliver energy to heart tissue to create precise lesions and manage blood flow. The company differentiates itself with an integrated AF-focused portfolio, combined with hands-on training and support for clinicians to ensure proper use in various surgical workflows. Its goal is to improve patient outcomes by providing reliable, easy-to-use devices and comprehensive clinician education.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Chester, Pennsylvania

Founded

1994

Get referred to AtriCure

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • On July 23, 2026, AtriCure raised 2026 revenue guidance to $602 million-$610 million.
  • Q2 2026 revenue hit $153.6 million, with adjusted EBITDA rising 78% to $27.3 million.
  • BoxX-NoAF reached 50% enrollment ahead of schedule, with data expected in 2027.

What critics are saying

  • Medtronic’s Affera Sphere-360 and Boston Scientific’s PFA systems attack AtriCure’s core surgery workflows.
  • BoxX-NoAF and LeAAPS still define upside; any trial failure erases expansion plans.
  • If PFA catheter adoption shifts surgeons away, AtriCure’s surgical ablation franchise shrinks permanently.

What makes AtriCure unique

  • AtriCure’s EnCompass and AtriClip platforms bundle surgical ablation, appendage exclusion, and training.
  • CryoSPHERE MAX halved freeze times and drove pain-management adoption in Q2 2026.
  • LeAAPS enrolled 6,573 patients, giving AtriCure the largest cardiac-surgery device trial.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Wellness Program

401(k) Company Match

Parental Leave

Pet Insurance

Employee Stock Purchase Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 12th, 2026
AtriCure targets $1B revenue by 2030 as pain management volumes jump 25%

AtriCure is targeting $1 billion in revenue by 2030, up from current guidance of $602–610 million annually. The company, which focuses on atrial fibrillation treatment and post-surgical pain management, has posted roughly 18% compound annual growth over five years, a 77% gross margin, and three consecutive quarters of net income. Pain management is driving expansion. Procedure volume grew about 25% in the latest quarter, aided by the cryoSPHERE MAX launch, which halves freeze time for certain procedures. Market penetration stands at around 20% in thoracic procedures, with room to grow in sternotomy and amputation applications. Clinical trials could expand AtriCure's market further. The BoxX-NoAF trial is expected to complete enrollment by year-end, with data due mid-2027. The larger LeAAPS trial may support broader AtriClip adoption if stroke-reduction results prove favourable.

Yahoo Finance
Jul 28th, 2026
AtriCure beats Q2 estimates with $153.6M revenue and 800% EPS surprise, raises full-year guidance

AtriCure reported second-quarter fiscal 2026 earnings on 23 July, with revenue of $153.6 million and adjusted EPS of $0.18, beating consensus estimates by $1.79 million and $0.16 respectively. The medical device company swung to a net profit of $9 million from a loss of $6.2 million in the same quarter last year. Gross margin improved to 77.2%, up 270 basis points year-on-year, driven by product innovation and efficiencies. US business grew 14% whilst worldwide revenue rose 13%. The pain management franchise saw 27% growth. AtriCure raised its full-year 2026 revenue guidance to $602 million-$610 million and adjusted EBITDA guidance to $85 million-$89 million. The company is enrolling patients in clinical trials targeting the post-operative atrial fibrillation market, valued at over $2 billion annually.

Yahoo Finance
Jul 24th, 2026
AtriCure reports $154M revenue, 13% growth and $9M net income in Q2 2026

AtriCure Inc reported strong second-quarter results with worldwide revenue of $154 million, representing 13% year-over-year growth. US revenue reached $125.6 million, up 13.6%, whilst international revenue grew 9.6% to $28 million. The medical device company achieved significant profitability improvements, posting net income of $9 million compared to a net loss of $6.2 million in the prior year. Adjusted EBITDA exceeded $27 million, with gross margin expanding to 77.2%. Pain management revenue led growth at 27.8% to $27.1 million, driven by adoption of cryoSPHERE MAX. Appendage management revenue increased 14.4% to $51.6 million, whilst open ablation revenue rose 12.1% to $40.9 million. The company raised full-year revenue guidance to $602-610 million, reflecting 12.5-14% growth over 2025. Adjusted EBITDA guidance was increased to $85-89 million. AtriCure also reported its BoxX-NoAF clinical study surpassed 50% enrollment ahead of schedule.

Yahoo Finance
Jun 4th, 2026
AtriCure accelerates heart disease trial by 12 months, beats Q1 revenue by $2M

AtriCure, a medical device company focused on atrial fibrillation treatments, reported first-quarter 2026 revenue of $141.2 million, up 14.3% year over year and exceeding analyst estimates by 1.4%. Growth was driven by a 28% increase in the pain management segment, led by its cryoSPHERE MAX probe. The company announced it has accelerated its BoxX-NoAF clinical trial timeline by 12 months, with patient enrollment now expected to complete by year-end and results potentially available in 2027 instead of 2028. The trial tests a minimally invasive procedure for treating atrial fibrillation. Following the results, Needham reiterated its Buy rating with a $45 price target on 6 May, citing the accelerated trial timeline as a major development that could unlock significant new market opportunities.

Yahoo Finance
May 12th, 2026
AtriCure targets 12–14% growth in 2026 with new devices and EnCompass platform expansion

AtriCure expects 12% to 14% revenue growth in 2026, driven by recent and upcoming product launches including cryoSPHERE MAX, cryoXT and new appendage-management devices. President and CEO Michael Carrel and CFO Angela Wirick discussed the outlook at a Bank of America fireside chat, following 15% revenue growth in 2025. The company's EnCompass ablation platform and AtriClip continue to show significant runway, with executives citing a large untapped cardiac-surgery market and strong surgeon adoption. A next-generation V-Clip appendage product is expected in 2027. AtriCure guided 2026 adjusted EBITDA at $80 million to $82 million whilst maintaining profitability improvements. The cryoXT device, targeting lower-extremity amputations, had a soft launch in late 2025 and is expected to contribute more meaningfully in the second half of 2026.